Head-To-Head Review: BioCardia (NASDAQ:BCDA) and C4 Therapeutics (NASDAQ:CCCC)

BioCardia (NASDAQ:BCDA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

20.6% of BioCardia shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 20.0% of BioCardia shares are held by company insiders. Comparatively, 8.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares BioCardia and C4 Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$480,000.00	25.95	-$11.57 million	($4.19)	-0.65
C4 Therapeutics	$20.76 million	10.88	-$132.49 million	($1.70)	-1.88

BioCardia has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for BioCardia and C4 Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	0	0	1	1	3.50
C4 Therapeutics	0	2	3	0	2.60

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 819.12%. C4 Therapeutics has a consensus target price of $11.60, suggesting a potential upside of 262.50%. Given BioCardia’s stronger consensus rating and higher probable upside, equities analysts clearly believe BioCardia is more favorable than C4 Therapeutics.

Profitability

This table compares BioCardia and C4 Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCardia	-1,999.77%	N/A	-208.38%
C4 Therapeutics	-313.35%	-42.45%	-27.55%

Risk & Volatility

BioCardia has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.95, suggesting that its share price is 195% more volatile than the S&P 500.

Summary

BioCardia beats C4 Therapeutics on 8 of the 15 factors compared between the two stocks.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.